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Abstract
Background and Aims: Fibroblasts growth factor 21 (FGF21), a liver-secreted endocrine factor involved in regulating
glucose and lipid metabolism, has been shown to be elevated in patients with non-alcoholic fatty liver disease (NAFLD). This
study aimed to evaluate the quantitative correlation between serum FGF21 level and hepatic fat content.
Methods: A total of 138 subjects (72 male and 66 female) aged from 18 to 65 years with abnormal glucose metabolism and
B-ultrasonography diagnosed fatty liver were enrolled in the study. Serum FGF21 levels were determined by an in-house
chemiluminescence immunoassay and hepatic fat contents were measured by proton magnetic resonance spectroscopy.
Results: Serum FGF21 increased progressively with the increase of hepatic fat content, but when hepatic fat content
increased to the fourth quartile, FGF21 tended to decline. Serum FGF21 concentrations were positively correlated with
hepatic fat content especially in subjects with mild/moderate hepatic steatosis (r=0.276, p=0.009). Within the range of
hepatic steatosis from the first to third quartile, FGF21 was superior to any other traditional clinical markers including ALT to
reflect hepatic fat content. When the patients with severe hepatic steatosis (the fourth quartile) were included, the
quantitative correlation between FGF21 and hepatic fat content was weakened.
Conclusions: Serum FGF21 was a potential biomarker to reflect the hepatic fat content in patients with mild or moderate
NAFLD. In severe NAFLD patients, FGF21 concentration might decrease due to liver inflammation or injury.
Citation: Yan H, Xia M, Chang X, Xu Q, Bian H, et al. (2011) Circulating Fibroblast Growth Factor 21 Levels Are Closely Associated with Hepatic Fat Content: A
Cross-Sectional Study. PLoS ONE 6(9): e24895. doi:10.1371/journal.pone.0024895
Editor: Aimin Xu, University of Hong Kong, China
Received May 12, 2011; Accepted August 19, 2011; Published September 16, 2011
Copyright:  2011 Yan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from National Key Technologies R&D Program (2008 BAI52B03; http://www.most.gov.cn/eng/programmes1/
200610/t20061009_36224.htm), the Major Project of Subject Construction of Shanghai Bureau of Health (08GWZX0203; http://www.smhb.gov.cn/), the Project of
Science and Technology of Shanghai Municipality (No. 07JC14011, No. 10411956400 and No. 10411962600; http://www.stcsm.gov.cn/structure/index.htm), the
Major Program of Shanghai Municipality for Basic Research (Grant No. 08dj1400601; http://www.stcsm.gov.cn/structure/index.htm) and the National Basic
Research Program of China (2011CB504004; http://www.973.gov.cn/Default_3.aspx). The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: zhongshan_endo@126.com
Introduction
Fibroblast growth factor 21 (FGF21) belongs to a distinct
‘‘endocrine’’ subgroup within the FGF superfamily, consisting of
FGF19, FGF21 and FGF23 [1–3]. Due to the lack of the con-
ventional FGF-heparin binding domain, these FGFs can escape the
body’s vast deposition of heparansulphate proteoglycans and can be
released into circulation and function as endocrine factors [4].
FGF21 is predominantly synthesized in liver, where it is induced
by the peroxisome proliferator-activated receptors, PPARa [5]and
PPARc [6]. In addition, the expression of FGF21 is also present in
pancreas, adipose, and muscle [7–10], FGF21 acts via FGF
receptors(FGFR), though the FGFR is widely distributed in almost
any tissue in the body, it is anticipated that FGF21 functions in a
selective set of tissues including liver, adipose and pancreas, where
b Klotho, a cofactor for FGF21 to activate FGFR, is expressed
selectively [10,11]. Physiologically, elevated FGF21 in liver can
induce gluconeogenesis, fatty acid oxidation and ketogenesis in the
context of prolonged fasting and starvation [12].
FGF21 has been shown to be an important protective factor
against various glucose and lipid metabolic disorders in animal
models [13–15]. For example, FGF21 activates glucose uptake in
adipocytes and protectes animals from diet-induced obesity [13].
Transgenic overexpression of FGF21 improves insulin sensitivity,
reduces blood glucose and triglyceride to near normal levels in
both ob/ob and db/db mice [13]. Similarly, in diabetic rhesus
monkeys, FGF21 significantly decreases fasting glucose, insulin,
glucagon and triglycerides [14]. A recent study showed that
treatment of recombinant murine FGF21 exerts beneficial effects
on hepatic steatosis [15].
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humans, though none of these studies directly supports the
metabolic regulation role of FGF21. Circulating FGF21 concen-
trations are increased in subjects who were either overweight or
had type 2 diabetes or impaired glucose tolerance [16,17]. Mai et
al. showed that both lipid infusion and artificial hyperinsulinemia
increase FGF21 levels in vivo [18]. However, another study found
that the function of FGF21 is closely related to lipid metabolism
instead of insulin sensitivity in humans [19]. FGF21 levels also
correlate with gamma-glutamyl transferase(c-GT) and aspartate
aminotransferase(AST), indicating the close relationship between
FGF21 and liver diseases [19].
Since liver is the major site for FGF21 expression and hepatic
steatosis is highly correlated with impairment of glucose and lipid
metabolism in humans, the relationship between hepatic steatosis
and FGF21 has been investigated in several recent studies. Li et al.
[20] reported that serum FGF21 levels were significantly higher in
the non-alcoholic fatty liver disease (NAFLD) group compared
with the controls and had a high positive correlation with
intrahepatic triglyceride content(r=0.662, p,0.001). This study,
along with recent reports by Dushay et al. [21] and Yilmaz et al.
[22] contributed greatly to expand our knowledge on plasma
FGF21 levels in patients with NAFLD, and indicate the role of
FGF21 in regulating hepatic lipid metabolism.
Although the aforementioned studies suggest that FGF21 could
be a potential biomarker to screen or monitor NAFLD patients
[23], the methods utilized to assess the severity of hepatic steatosis,
such as B-mode ultrasound or pathological score system, were
qualitative or semi-quantitative and did not reflect the quantitative
association between serum FGF21 and hepatic fat content
accurately. Moreover, in the study by Li et al., liver biopsies were
obtained from patients undergoing resection for benign liver
disease and the number of patients with precise information of
hepatic fat content was rather small, which might preclude a
reliable conclusion [20].
In the current study, we used
1H Magnetic Resonance
Spectroscopy (
1H MRS) to quantify hepatic fat content in a
relatively large number of participants with impaired glucose
metabolism and without known liver disease except for different
degree of hepatic steatosis, and further analyzed the quantitative
association between serum FGF21 level and hepatic fat content.
Methods
Ethics Statement
The study was approved by the human research ethics
committee of Zhongshan hospital, and was conducted according
to the principles of the Declaration of Helsinki. Written informed
consent was obtained from all subjects.
Subjects
The subjects were participants from a clinical intervention study
named Role of Pioglitazone and Berberine in the Treatment of
Non-Alcoholic Fatty Liver Disease (http://clinicaltrials.gov/,
NCT00633282), which was an open, randomized, controlled
clinical trial. From March 2008 to July 2010, 160 subjects (88 men
and 72 women) were recruited initially from the outpatients
department of endocrinology, Shanghai Zhongshan Hospital,
China. All participants were diagnosed as impaired glucose
regulation(including impaired fasting glucose or impaired glucose
tolerance or both) or newly diagnosed diabetes and fatty liver by B
ultrasonography during clinical screening tests according to the
inclusion criteria of the clinical trial. No subjects took anti-diabetic
medications(see exclusion criteria below). (details on the inclusion
criteria of the clinical trial: http://clinicaltrials.gov/ct2/show/
NCT00633282?term=NCT00633282&rank=1).
Szczepaniak and colleagues [24] had analyzed the distribution
of hepatic fat content (HFC) in 2,349 participants from the Dallas
Heart Study by
1H MRS and found 5.56% could be considered a
cut-off for NAFLD. According to the study , we took HFC
.5.56% as a criteria for diagnosis of NAFLD in our study too.
All subjects underwent comprehensive physical examinations,
routine biochemical analyses of blood, 75g oral glucose tolerance
test, hepatitis B surface antigen, hepatitis C virus antibody and
1H
MRS. All participants completed a uniform questionnaire
containing questions about the histories of present and past
illnesses and medical therapy. Subjects with the following
conditions were excluded from this study: (1) alcohol consump-
tion$140 g/week for men or 70 g/week for women; (2) acute or
chronic virus hepatitis; (3)biliary obstructive diseases; (4)drug-
induced liver disease; (5) total parenteral nutrition;(6) autoimmune
hepatitis; (7) Wilson’s disease; (8) known hyperthyroidism or
hypothyroidism; (8) presence of cancer; (9) current treatment with
systemic corticosteroids; (10) patients who have taken or are taking
oral hypoglycemic or hypolipidemic drugs and (11) pregnancy. As
the intensity of interventions in the clinical trial mentioned above
was mild, patients with obvious metabolic abnormalities were
excluded for the health of patients, including diabetics patients
with hemoglobin A1c (HbA1c).7.5% on initial visit ; serum
triglyceride $5.0 mmol/L and patients with significantly impaired
liver function [Alanine aminotransferase(ALT) or AST$150 U/
L]. Among the 160 subjects, the study was performed on 138
subjects (72 men and 66women) aged from 18 to 65 years old
excluding 22 subjects who met the above exclusion criteria.
Anthropometric and biochemical measurements
Body mass index (BMI) was calculated as the weight in
kilograms divided by the square of the height in meters. Waist
circumference was measured at the midpoint between the inferior
costal margin and the superior border of the iliac crest on the
midaxillary line. Waist–hip ratio (WHR) was calculated as waist
circumference divided by hip circumference. Blood pressure(BP)
was measured three times with 5 minute intervals each time in the
seated position with a mercury sphygmomanometer in the
morning,The first and fifth Korotkoff sounds were used to
designate systolic(SBP) and diastolic BP(DBP), respectively. and
the average of the three BPs was used as the final BP.
The biochemical indexes were measured on a Hitachi 7600
analyzer (Hitachi, Tokyo, Japan). Serum fasting glucose (FBG) and
2 hour glucosewere measured by the glucose oxidase method.
Serum levels of total cholesterol (TC), triglycerides (TG), high
density lipoprotein cholesterol (HDL-c), and low density lipopro-
tein cholesterol (LDL-c) were determined enzymatically. Apolipo-
protein A, B, E (APOA, APOB, APOE) were measured by the
immunoturbidimetric assay. ALT, AST,c-GT and lactate dehy-
drogenase(LDH)were measured by standard enzymatic methods.
HbA1c was measured by high performance liquid chromatogra-
phy with HLC-723G7 automated glycohemoglobin analyzer
(Tosoh, Tokyo, Japan).
Measurement of serum FGF21
Circulating FGF21 concentrations were measured with an in-
house chemiluminescence immunoassay [25] (Antibody and
Immunoassay Services, University of Hong Kong). The assay
was proven to be highly specific to human FGF21 and did not
cross-react with other members of the FGF family (for details see
Supplement S1).
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Localized proton magnetic resonance spectroscopy (
1H MRS)
images of the liver were acquired using a 1.5-T Avanto MR system
(Siemens AG, Erlangen, Germany) by an experienced radiologist.
Sagittal, coronal, and axial slices through the right lobe of the liver
were acquired, and an 8 cm
3 volume of liver parenchyma was
selected for further study. Spectra were collected using a Q-body
coil for radiofrequency transmission and signal reception and a
double-echo point-resolved spectroscopy sequence for 128 acqui-
sitions. Areas of resonances from protons of water and methylene
groups in fatty acid chains were obtained with a time-domain
nonlinear fitting routine using commercial software (Syngo
spectroscopy VB15, Siemens AG). HFC was calculated by dividing
the integral of the methylene groups in fatty acid chains of the
hepatic triglycerides by the sum of methylene groups and water
[26].
Statistical analysis
Statistical analyses were performed with SPSS software version
13.0 (SPSS, Inc. Chicago, IL). Normally distributed data were
expressed as means 6 SD. Data that were not normally
distributed, as determined using Kolmogorox–Smirnov test, were
logarithmically transformed before analysis and expressed as
median with interquartile range. One-way ANOVA was used for
comparisons among groups, and multiple testing was corrected
using LSD method (Equal Variances Assumed) or Games-Howell
method (Equal Varance not assumed). Pearson’s correlations and
multiple stepwise regression analysis were used to examine the
association of HFC, serum FGF21, and other parameters. In all
statistical tests, p values ,0.05 were considered significant.
Results
Among 138 subjects, 76 had impaired glucose regulation(FBG
$5.6 mmol/L and/or a two hour glucose value $7.8 mmol/L)
and 62 had newly diagnosed diabetes(FBG$7.0 mmol/L and/or
a two hour glucose value$11.1 mmol/L).
Hepatic fat contents (HFCs) of all the study subjects determined
by
1H MRS were distributed normally from 2.47% to 81.95%
with a mean and standardized deviation of 32.30% and 15.95%,
respectively. Using HFC .5.56% as a criteria for diagnosis of
NAFLD [24], 136 subjects of the study was NAFLD.
The general characteristics of the subjects (Table 1)
By dividing the distribution of HFC into quartile, we found that
there were more male subjects than female subjects in groups with
Table 1. The general characteristics of the study subjects.














male/female 24/17 21/10 16/21 11/18 0.020
Age (years) 51.6168.63 49.8169.19 48.0469.81 53.11610.60 0.228
BMI (kg/m
2) 26.2662.49 27.7764.06 28.2764.18
* 27.6763.72 0.205
Waist (cm) 92.1066.47 94.30612.04 95.5969.71 93.6968.55 0.569
WHR 0.9360.05 0.9460.08 0.9460.06 0.9460.06 0.995
SBP (mmHg) 122.46615.64 129.52612.53 122.30612.10 126.62616.04 0.169
DBP (mmHg) 77.7366.71 82.98611.76
* 79.2867.54 79.51611.10 0.213
FBG (mmol/L) 6.4461.17 6.4461.13 6.0260.74 6.2860.80 0.319
2hBG (mmol/L) 11.5663.36 10.2763.15 10.1962.79 11.5563.01 0.163
HbA1c(%) 6.2760.79 6.4360.71 6.2860.62 6.4460.65 0.707
TC(mmol/L) 4.9660.79 5.1460.85 5.4760.74
* 5.4060.98 0.091
TG (mmol/L) 1.9761.07 2.0360.78 2.1660.95 2.3260.88 0.260
HDL-c (mmol/L) 1.1360.24 1.1260.23 1.2060.28 1.1860.23 0.576
LDL-c (mmol/L) 3.1460.97 3.2160.91 3.3460.77 3.1760.89 0.839
APOA (g/L) 1.2060.23 1.2060.21 1.2960.26 1.2960.22 0.166
APOB (g/L) 0.9460.22 0.9660.16 1.0360.16
* 1.0560.24
* 0.071
APOE (mg/L) 44.91611.42 47.97612.50 49.33611.89 54.13613.74
* 0.063




AST (U/L) 22.3266.94 25.2569.66 29.21610.54
* 37.07615.50
*#& 0.000
c-GT (U/L) 41.11636.10 50.86636.94 38.31621.82 59.96642.99
*& 0.057
LDH (U/L) 181.27626.00 212.86684.70 193.29631.28 205.96634.91
* 0.066
*: Compared with group Q1 p,0.05;
#: Compared with group Q2 p,0.05;
&: Compared with group Q3 p,0.05.
BMI: Body mass index;WHR: waist-to-hip ratio; SBP: systolic blood pressure; DBP: diasystolic blood pressure; FBG: fasting blood glucose; 2hBG: 2 h postload blood
glucose. TC: total cholesterol; TG: triglyceride; HDL-c: high density lipoprotein cholesterol; LDL-c: low density lipoprotein cholesterol; APOA: apolipoprotein A; APOB:
apolipoprotein B; APOE: apolipoprotein E; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; c-GT: c-glutamyl transpeptidase; LDH: lactate
dehydrogenase.
doi:10.1371/journal.pone.0024895.t001
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hepatic fat content (Q3 and Q4) there were more female subjects.
The four groups did not differ in most of metabolic parameters,
except that ALT and AST were elevated gradually with the increase
of HFC (both p,0.001). ALT was 27.52615.20 U/L, 37.046
17.45 U/L, 43.28622.16 U/L, 61.11637.27 U/L and AST was
22.3266.94 U/L, 25.2569.66 U/L, 29.21610.54 U/L, 37.076
15.50 U/L when HFC was in Q1,Q2,Q3,Q4, respectively. and c-
GT showed a tendency to increase when HFC increased gradually
(p=0.057), with highest value up to 59.96 U/L in the fourth
quartile, but a obvious drop to 38.31 U/L in the third quartile.
HFC and FGF21
With the increase of HFC, serum FGF21 also increased
progressively in patients with HFC no more than the fourth quartile.
The FGF21 concentrations were 194.126126.96 pg/ml, 219.656
141.74 pg/ml and 326.446149.47 pg/ml when HFC was in Q1,
Q2, Q3, respectively. Interestingly, once HFC further increased to
the fourth quartile, FGF21 tended to decline to 258.756124.69 pg/
ml. (compared with the third quartile, p=0.059) (Figure S1A).
In light of the fact that FGF21 increased progressively when HFC
was increased from the first quartile to the third quartile, but
decreased in the fourth quartile, we analyzed the association be-
tween serum FGF21 concentration and HFC in subjects within the
first three quartiles of HFC and all subjects, respectively (Figure S2).
When HFC wasin Q1 to Q3, there was a significant positive
association between FGF21 and HFC (r=0.276, p=0.009);
However, the significant association between HFC and FGF21 no
longer existed when HFC was in Q4 (r=20.087, p=0.671).
Also, we analyzed the association between HFC and other
parameters in subjects within the first three quartiles of HFC and all
subjects, respectively. In univariate correlation analyses, HFC in
Q1–Q4 positively associated with AST (r=0.487, p,0.001), ALT
(r=0.436, p,0.001), LDH (r=0.325, p=0.001), TG (r=0.296,
p,0.001), APOE(r=0.252, p=0.011);c-GT(r=0.238, p=0.005),
TC (r=0.211, p=0.014), APOA (r=0.200, p=0.028); APOB
(r=0.199, p=0.028), and sex (r=0.172, p=0.043). After adjust-
ment for sex, age and BMI, HFC in Q1–Q4 still positively
associated withAST(r=0.461,p,0.001))ALT(r=0.443,p,0.001),
APOB (r=0.277, p=0.029), and TC (r=0.272, p=0.033).
Similarly, HFC in Q1–Q3 positively associated with ALT
(r=0.378, p,0.001), AST (r=0.373, p,0.001), TG (r=0.325,
p,0.001), LDH (r=0.244, p=0.026), APOB (r=0.241, p=0.019),
TC (r=0.214, p=0.026), and age (r=20.206, p=0.033). After
adjustment for sex, age and BMI, HFC in Q1–Q3 still positively
associated with ALT(r=0.402, p=0.008) APOB (r=0.350,
p=0.021) AST (r=0.339, p=0.026). Differently, HFC in Q4
negatively associated only with WHR (r=20.419, p=0.024) and
the association was insignificant after adjustment for sex, age and
BMI (Table 2).
Table 2. Correlations of HFC with serum FGF21 and other parameters.
Variables HFC(Q1–4) HFC(Q1–3) HFC(Q4)
rp r * p *rp r * p *rp r * p *
Sex(1=M;2=F) 0.172 0.043 22 0.087 0.369 22 0.119 0.539 22
Age 20.009 0.916 22 2 0.206 0.033 22 0.050 0.798 22
BMI 0.110 0.206 22 0.131 0.186 22 0.176 0.361 22
FGF21 0.198 0.047 0.247 0.053 0.276 0.009 0.543 ,0.001 20.087 0.617 20.038 0.898
Waist 0.074 0.391 20.118 0.363 0.082 0.395 0.071 0.650 0.035 0.857 20.424 0.131
WHR 20.030 0.730 20.054 0.677 20.004 0.967 0.074 0.637 20.419 0.024 20.463 0.096
SBP 0.006 0.947 20.009 0.946 0.008 0.938 0.134 0.390 20.174 0.366 20.201 0.490
DBP 20.018 0.836 20.029 0.823 0.033 0.737 0.143 0.361 20.114 0.558 20.170 0.560
FBG 20.031 0.724 20.102 0.431 20.140 0.151 20.256 0.097 0.142 0.479 0.224 0.442
2hBG 0.026 0.768 20.085 0.512 20.108 0.269 20.163 0.297 20.039 0.846 20.437 0.118
HbA1c 0.063 0.489 0.062 0.635 0.004 0.968 0.058 0.714 0.116 0.563 20.029 0.921
TC 0.211 0.014 0.272 0.033 0.214 0.026 0.299 0.051 0.131 0.497 20.005 0.987
TG 0.296 ,0.001 0.213 0.097 0.325 0.001 0.231 0.137 0.002 0.994 20.369 0.194
HDL-c 0.009 0.916 20.087 0.502 20.104 0.286 20.152 0.330 0.345 0.067 0.276 0.340
LDL-c 0.059 0.492 0.201 0.117 0.091 0.348 0.193 0.215 0.067 0.729 0.121 0.679
APOA 0.200 0.028 0.211 0.099 0.199 0.053 0.285 0.064 0.118 0.564 0.089 0.762
APOB 0.199 0.028 0.277 0.029 0.241 0.019 0.350 0.021 20.180 0.368 20.090 0.759
APOE 0.252 0.011 0.226 0.078 0.154 0.177 0.184 0.238 0.021 0.923 0.041 0.890
ALT 0.436 ,0.001 0.443 ,0.001 0.378 ,0.001 0.402 0.008 0.123 0.541 0.055 0.853
AST 0.487 ,0.001 0.461 ,0.001 0.373 ,0.001 0.339 0.026 0.072 0.710 0.081 0.784
c-GT 0.238 0.005 0.225 0.079 0.150 0.121 0.131 0.402 0.033 0.864 0.018 0.952
LDH 0.325 0.001 0.162 0.210 0.244 0.026 0.023 0.883 0.371 0.062 0.193 0.509
BMI: Body mass index;WHR: waist-to-hip ratio; SBP: systolic blood pressure; DBP: diasystolic blood pressure; FBG: fasting blood glucose; 2hBG: 2 h postload blood
glucose. TC: total cholesterol; TG: triglyceride; HDL-c: high density lipoprotein cholesterol; LDL-c: low density lipoprotein cholesterol; APOA: apolipoprotein A; APOB:
apolipoprotein B; APOE: apolipoprotein E; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; c-GT: c-glutamyl transpeptidase; LDH: lactate
dehydrogenase.
*sex,age and BMI adjusted.
doi:10.1371/journal.pone.0024895.t002
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clinical metabolic parameters in reflecting HFC, we conducted
multivariate stepwise regression analysis between HFC and
variables which are significant in univariate analysis and relevant
to HFC, including: sex, FGF21, ALT, AST, c-GT, LDH, TC,
TG, APOA, APOB, APOE when HFC was in Q1–Q4, and age,
FGF21, ALT, AST, LDH, TC, TG, APOB when HFC was in
Q1–Q3. FGF21 has already been shown to be correlated with age
in some studies [27], therefore, age also was adjusted in the
multiple regression analysis when HFC was in Q1–Q4. We found
that in all subjects, AST and sex(female) were independently
associated with HFC (all p,0.05). However, when the subjects
with the highest quartile of HFC were excluded from the analysis,
FGF21 became the strongest factors independently associated with
HFC (Table 3).
Discussion
In the present study, we demonstrated the close association of
serum FGF21 concentrations with intrahepatic fat content in 138
patients with abnormal glucose metabolism and with B ultra-
sound-diagnosed hepatic steatosis, whose hepatic fat content were
distributed in a large range (2.47%–81.95%). To the best of our
knowledge, this study is the first to show the quantitative
correlation between serum FGF21 concentrations and hepatic
fat content measured by
1H MRS in patients with impaired
glucose metabolism. Interestingly, we found that in patients with
mild or moderate hepatic steatosis (HFC was in Q1–Q3), FGF21
was the strongest factors independently associated with HFC
among all metabolic parameters measured. However, when the
hepatic fat content increased to the fourth quartile, serum FGF21
concentration no longer increased, but tended to decrease on the
contrary.
A previous study has shown that in 17 patients with pathological
liver triglycerides ranged from 10% to 40%, serum FGF21
concentration was highly positively correlated with hepatic fat
content [20], similar to the results of our current study. Mounting
evidences have suggested FGF21 as a protective metabolic
regulator against a series of abnormalities in glucose and lipid
metabolism. FGF21 is most abundantly expressed in the liver and
can be directly induced by free fatty acids (FFAs), through PPARa,
whose responsive elements had been found in the promoter
regions of human FGF21 genes [28]. Liver is the main processing
site of FFAs released from white adipose tissue (WAT). Therefore,
hepatic cells are able to directly ‘‘sense’’ the alteration of
circulating FFAs and regulate the concentration of FGF21
accordingly. A recent study has reported that circulating FGF21
level was closely related with the daily oscillation of free fatty acids
[25], which also supported the FFAs-dependent activation of
FGF21 in humans. Under the condition of obesity and insulin
resistance, excessive influx of FFAs to the liver would induce
FGF21 over-expression, and then elevated FGF21 could in turn
decrease the level of serum FFAs through the inhibition of lipolysis
in WAT [29]and inhibit the hepatic triglycerides generation and
hepatic steatosis through promotion of fatty acid oxidation and
ketogenesis [30]. Therefore, it is possible that the elevation of
FGF21 is a hepatic protective response to the whole-body lipid
metabolic burden influx to the liver, and the hepatic fat content
directly reflect the excessive FFAs that enter the lipid synthesis
pathway in the liver. Therefore, the serum FGF21 increases
independently with the degree of hepatic steatosis to maintain a
balance of hepatic lipid metabolism. In addition, since liver is the
predominant organ for FGF21 production and action, it is possible
that fat accumulated in the hepatic cell could also directly
stimulate the secretion of FGF21 or cause an attenuated functional
response to FGF21 (FGF21 resistance), thus leading to a
compensatory FGF21 up-regulation.
Interestingly, when hepatic fat content increased to the fourth
quartile, we found that the serum FGF21 concentration began to
decrease on the contrary (Figure S1A). In line with our finding, a
recent study reported that serum FGF21 levels were increased in
individuals with NASH, but FGF21 level in NASH patients was
much lower than that in NAFLD patients [21]. In the current
study, in patients with hepatic fat content in the fourth quartile,
the serum concentration of ALT, a well-established marker of
hepatic injury, was also elevated (Table 1, Figure S1B), indicating
the presence of hepatic injury in these patients. Therefore we
speculated that the decrease of FGF21 in patients with severe
hepatic steatosis might also be explained by the hepatic cell injury
or death caused by lipoxicity and hepatic inflammation, so that the
remaining hepatic cells were unable to produce as much FGF21 as
needed. If our assumption turned out to be true, then a decrease of
FGF21 level in NAFLD patient might indicate a decompensatory
stage of the disease and might accompany with an acute
deterioration of a series of metabolic disorders.
As we have shown that the FGF21 concentration in patients
with mild or moderate hepatic steatosis was elevated in parallel
with serum ALT level, but this balance would break in severe
NAFLD patients, whose biochemical indexes will show an
obviously elevated ALT concentration but only a slight unparallel
elevation of FGF21 concentration probably due to the presence of
hepatic injury. Therefore, it is possible that the insufficiency of
FGF21 relative to elevation of ALT concentration might be a
warning for hepatic cell injury clinically. Our study also found in
patients with hepatic fat content no more than the fourth quartile,
serum FGF21 was better than any metabolism-related parameters,
including ALT, AST and TG, to reflect the hepatic fat content.
Traditionally, ALT was most commonly used parameter to reflect
hepatic impairment including NAFLD. However, our study
indicated that FGF21 might be a better serum biomarker for
NAFLD than ALT, though the clinical value of FGF21 as a
NAFLD biomarker still need to be validated by further large-scale
studies in the general population.
There are several limitations in this study. Firstly, since the
study detected the quantitative correlation between FGF21 and
hepatic fat content in a specific group of participants with
abnormal glucose metabolism and B ultrasound-diagnosed hepatic
steatosis, the average hepatic fat content in our subjects was much
Table 3. Multiple stepwise regression analysis.
Independent variables Standardized coefficient Beta p value
Model 1 (HFC: Q1–Q4)
AST 0.514 ,0.001
sex 0.215 0.034
Model 2 (HFC: Q1–Q3)
FGF21 0.409 ,0.001
ALT 0.340 0.002
Model 1 HFC (Q1–Q4) was the dependent variable, independent variables were
age and the variables which are significant in univariate analysis and relevant to
HFC, including : sex(1=M, 2=F), FGF21, ALT, AST, c-GT, LDH, TC, TG, APOA,
APOB, APOE.
Model 2 HFC (Q1–Q3) was the dependent variable, independent variables were
the variables which are significant in univariate analysis and relevant to HFC,
including : age, FGF21, ALT, AST, LDH, TC, TG, APOB.
doi:10.1371/journal.pone.0024895.t003
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to determine the clinical value of FGF21 as a biomarker for
NAFLD in the general population. Secondly, as a non-invasive
imaging technique,
1H MRS can detect fatty infiltration of the
liver, but unlike ‘‘gold standard’’ liver biopsy, it is limited in its
ability to detect coexisting inflammation or fibrosis. However, in
this article, we concerned more about the relationship of HFC
with FGF21 and other metabolic parameters than the pathological
changes of liver, and liver biopsy is an invasive examination which
can not be accepted easily by patients, furthermore, it has been
demonstrated that histology correlates well with
1H MRS in
evaluating hepatic triglyceride content [31]. Several clinical trials
[32,33] on NAFLD have used
1H MRS as an outcome
measurement. Therefore,
1H MRS may be a more appropriate
reference standard than histology in accurately assessing fat
content, especially in a relatively large sample study. Thirdly, we
speculated the presence of hepatic injury in patients with severe
hepatic steatosis according to the ALT concentration, a simple
marker for hepatic injury, biopsy-proven data are needed to
confirm the hepatic pathological features in severe NAFLD
patients in our future works.
In summary, our study demonstrated that FGF21 was strongly
correlated with the hepatic fat content in people with mild or
moderate hepatic steatosis and could better reflect hepatic fat
content than any known serum parameters. Furthermore, we
found a decrease of FGF21 in patients with severe hepatic
steatosis, which might indicate the presence of hepatic injury.
These results support the role of FGF21 as a potential biomarker
for NAFLD and further suggest an important role of FGF21 in
regulating hepatic lipid metabolism in humans.
Supporting Information
Figure S1 Levels of serum FGF21 and ALT in patients
with different HFC quartiles. (A)serum FGF21 concentra-
tions (pg/ml) (B) serum ALT levels (U/L). *: p,0.05, significant
difference compared with group Q1; #: p,0.05, significant
difference compared with group Q2. Compared with Q3, serum
FGF21 of Q4 was decreased, p=0.059.
(TIF)
Figure S2 Association between serum FGF21 and HFC
when (A) HFC was in the range of Q1–Q4; (B) HFC was in
the range of Q1–Q3; (C) HFC was in the range of Q4.
(TIF)
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